systemic lupus erythematosus

systemic lupus erythematosus
Name	Systemic lupus erythematosus
Field	Rheumatology, Immunology
Symptoms	Fatigue, joint pain, rash, fever, organ involvement
Onset	Any age (commonly childbearing years)
Causes	Autoimmune, genetic, environmental
Risks	Female sex, certain ancestries
Diagnosis	Clinical criteria, serology, biopsy
Treatment	Immunosuppression, symptom control

systemic lupus erythematosus is a chronic autoimmune disorder characterized by multisystem inflammation and diverse clinical manifestations that can affect the skin, joints, kidneys, nervous system, and serous membranes. It presents with periods of flares and remissions and requires multidisciplinary care often involving specialists in rheumatology, nephrology, dermatology, and neurology. Recognition hinges on integrating clinical features with immunologic testing and sometimes histopathology, and long-term management balances immunosuppression with prevention of treatment-related adverse effects.

Signs and symptoms

Patients commonly report fatigue, arthralgia, and fever along with distinctive cutaneous findings such as malar rash and photosensitivity; these presentations prompt evaluation by clinicians in settings like hospital clinics associated with Mayo Clinic, Johns Hopkins Hospital, Cleveland Clinic, Massachusetts General Hospital, and Mount Sinai Hospital. Musculoskeletal manifestations include nonerosive arthritis and myalgias that lead to referrals to specialists at centers such as Hospital for Special Surgery, Royal National Hospital for Rheumatic Diseases, Charité – Universitätsmedizin Berlin, Karolinska University Hospital, and Surgical Hospital of Helsinki University. Renal involvement causes proteinuria and hematuria and often necessitates consultation with nephrologists at institutions like Necker–Enfants Malades Hospital, Toronto General Hospital, St. Bartholomew's Hospital, Prince of Wales Hospital, and Groote Schuur Hospital. Neuropsychiatric symptoms range from cognitive dysfunction to seizures and stroke-like events managed in departments such as Addenbrooke's Hospital, Guy's and St Thomas' NHS Foundation Trust, Royal Free Hospital, UCLH, and Leiden University Medical Center. Serositis presenting as pleuritis or pericarditis leads to imaging and care at sites like Cedars-Sinai Medical Center, Barnes-Jewish Hospital, University of California, San Francisco Medical Center, King's College Hospital, and Royal Infirmary of Edinburgh.

Causes and pathophysiology

Etiology is multifactorial with interactions among genetic predisposition, epigenetic changes, hormonal influences, and environmental triggers identified in cohorts studied at Broad Institute, Wellcome Sanger Institute, National Institutes of Health, Institut Pasteur, and Ragon Institute. Genetic associations include variants in genes such as those implicated by research groups at Harvard Medical School, Stanford University School of Medicine, University of Oxford, Yale School of Medicine, and University of Cambridge. Dysregulated innate and adaptive immunity with loss of tolerance, autoantibody production (including anti-dsDNA and anti-Smith), immune complex deposition, complement activation, and type I interferon signatures have been characterized in studies from Rockefeller University, Imperial College London, Fred Hutchinson Cancer Center, Scripps Research Institute, and Karolinska Institutet. Environmental triggers implicated include ultraviolet radiation, infections, and certain medications reported in surveillance by Centers for Disease Control and Prevention, World Health Organization, European Medicines Agency, Food and Drug Administration, and Medical Research Council–sponsored consortia. Hormonal modulation and female predominance have been explored in programs at Oxford University Hospitals, University of Pennsylvania Health System, Duke University Hospital, John Radcliffe Hospital, and Vall d'Hebron University Hospital.

Diagnosis

Diagnosis integrates clinical criteria, serologic testing (antinuclear antibody, anti-dsDNA, anti-Smith, antiphospholipid antibodies), complement levels, urinalysis, and tissue biopsy when indicated; these standards are promulgated through guidelines from organizations such as American College of Rheumatology, European League Against Rheumatism, British Society for Rheumatology, Asia Pacific League of Associations for Rheumatology, and Pan American League of Associations for Rheumatology. Specialized laboratories and centers that perform testing and histopathologic review include Mayo Clinic Laboratories, Quest Diagnostics, ARUP Laboratories, Pathology Department at Johns Hopkins Hospital, and Karolinska University Hospital Pathology. Imaging modalities including MRI, echocardiography, and ultrasound are applied in practices at Mount Sinai Hospital, Hospital for Special Surgery, Royal Brompton Hospital, Necker–Enfants Malades Hospital, and Guy's and St Thomas' NHS Foundation Trust. Diagnostic challenges and differential diagnoses are addressed in multidisciplinary conferences at Cleveland Clinic, Massachusetts General Hospital, UCSF Medical Center, Toronto General Hospital, and Charité – Universitätsmedizin Berlin.

Treatment and management

Management combines symptomatic treatment, immunomodulation, organ-specific therapy, and preventive care coordinated among specialists at centers like Mayo Clinic, Johns Hopkins Hospital, Cleveland Clinic, Massachusetts General Hospital, and Mount Sinai Hospital. First-line therapies for mild disease include antimalarials such as hydroxychloroquine, with implementation strategies developed at Vanderbilt University Medical Center, Brigham and Women's Hospital, Hospital Universitario La Paz, AP-HP, and St. Thomas' Hospital. Glucocorticoids and conventional immunosuppressants (azathioprine, mycophenolate mofetil, cyclophosphamide) are used for moderate-to-severe disease under protocols from National Institutes of Health, European Medicines Agency, Food and Drug Administration, NICE, and Institute for Clinical and Economic Review. Biologic therapies such as belimumab and rituximab have been evaluated in trials conducted at Genentech, AstraZeneca, Roche, GlaxoSmithKline, and Novartis with implementation in clinical practice at referral centers including UCSF Medical Center, Royal Free Hospital, St. Bartholomew's Hospital, Toronto General Hospital, and Royal Brisbane and Women's Hospital. Supportive care includes anticoagulation for antiphospholipid syndrome, renal replacement therapy for end-stage renal disease, and rehabilitation services available at Mayo Clinic, Barnes-Jewish Hospital, Cedars-Sinai Medical Center, Singapore General Hospital, and Groote Schuur Hospital.

Prognosis and complications

Prognosis has improved with early diagnosis and modern therapy but varies by organ involvement, access to care, and comorbidities; longitudinal cohorts and registries maintained by European Lupus Study Group, Lupus Foundation of America, Wellcome Trust, NIH Lupus Cohort, and British Society for Rheumatology document outcomes. Major complications include lupus nephritis, cardiovascular disease, infections due to immunosuppression, neuropsychiatric lupus, and pregnancy morbidity; management of these complications involves multidisciplinary teams at Cleveland Clinic, Mayo Clinic, Johns Hopkins Hospital, Massachusetts General Hospital, and Karolinska University Hospital. Mortality is influenced by disease activity, organ damage accrual, and treatment-related adverse events documented in studies from Framingham Heart Study, Global Burden of Disease Study, World Health Organization, Centers for Disease Control and Prevention, and national registries in Sweden, Denmark, United Kingdom, United States, and Brazil.

Epidemiology

Prevalence and incidence vary regionally, with higher rates reported among people of African, Hispanic, and Asian ancestry in surveillance reports from United States Census Bureau–linked studies, Brazilian Institute of Geography and Statistics, Statistics Canada, Office for National Statistics, Australian Bureau of Statistics, and cohort studies in South Africa, Japan, India, China, and Mexico. Peak onset is most often in women of childbearing age, a pattern observed in registries maintained by Lupus Foundation of America, European Lupus Study Group, Asia Pacific Lupus Collaboration, Latin American Lupus Consortium, and national health databases in France, Germany, Italy, Spain, and Netherlands. Public health initiatives and research funding for epidemiologic studies have been supported by National Institutes of Health, Wellcome Trust, European Commission, Bill & Melinda Gates Foundation, and national health ministries in multiple countries.

Category:Autoimmune diseases